SC
DMII

Sculptor Capital’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Sculptor Capital’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-500,000
Closed -$4.99M – 461
2026
Q1 		$4.99M Hold
500,000
– – 0.05% 180
2025
Q4 		$4.95M Buy
+500,000
New +$4.94M 0.05% 199

Other funds holding DMII

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Sculptor Capital's DMII Position: Q2 2026 in Review

Sculptor Capital sold out of Drugs Made In America Acquisition II Corp (DMII) in Q2 2026, closing a stake of 500,000 shares — an estimated $4.99M sold.

Sculptor Capital first reported a position in DMII in Q4 2025 and held it in 2 quarters. The position peaked at $4.99M in Q1 2026. 68 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • Sculptor Capital reported no remaining Drugs Made In America Acquisition II Corp position as of Q2 2026 after selling out during the quarter.
  • Sculptor Capital sold 500,000 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $4.99M.
  • Sculptor Capital first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and held it in 2 quarters.
  • Sculptor Capital's Drugs Made In America Acquisition II Corp position peaked at $4.99M in Q1 2026.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Sculptor Capital's 13F filing for Q2 2026, filed 14 Aug 2026.